Abstract Library

#4287 Challenges in access to peptide receptor radionuclide therapy (PRRT) in developing countries – Insights from patient advocacy perspective

Introduction: As patient advocates and advocacy groups emerge as pivotal players in promoting access to healthcare, we explore their role in promoting radionuclide therapy in NETs.

Conference:

Presenting Author: Dureja S

Authors: Dureja S,

Keywords: Neuroendocrine tumour, Patient Advocacy, PRRT, Theranostics, Developing countries,

#3466 Improving understanding of neuroendocrine tumors (NETs) – A key to improving patient outcomes

Introduction: The International Neuroendocrine Cancer Alliance (INCA) is a global umbrella organization advocating on behalf of neuroendocrine patients to improve time to diagnosis, care and research.

Conference:

Presenting Author: McDonnell M

Authors: McDonnell M, Kolarova T, van Genechten D, Gellerman E, Dureja S,

Keywords: neuroendocrine, awareness, education, improve, outcome, global,

#2928 Survey of Challenges in Access to Diagnostics and Treatment for Neuroendocrine Tumour (NET) Patients (SCAN) – Assessment of Early Diagnosis

Introduction: SCAN measured global readiness to provide diagnostics and treatments for NET patients in terms of awareness, availability, quality and affordability.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Van Genechten D

Authors: Van Genechten D, McDonnell M, Rodien-Louw C, Dureja S, Leyden S,

Keywords: Neuroendocrine Tumours, Survey, Earlier diagnosis,

#2210 213 Bi and Ac 225 DOTATOC Receptor Labeled Targeted Alpha-Radionuclide Therapy in Neuroendocrine Tumors Refractory to Beta Radiation - Early Experience

Introduction: Radiopeptide therapy using a somatostatin analogue labeled with alpha emitters Actinium 225 and Bismuth 213 DOTATOC is a novel therapeutic option in metastatic neuroendocrine tumors (NET), with few alternative therapeutic options for patients with beta refractory disease. We report the first experience with 213Bi and Ac225 DOTATOC targeted alpha therapy (TAT) in treatment of well differentiated metastatic NETs at a tertiary care hospital in India.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Dureja S

Authors: Dureja S, Sen I, Pant V, Thak P,

Keywords: Targeted alpha therapy, TAT, PRRT, neuroendocrine tumors, beta refractory,

#1817 Dosimetric Analyses of Patients with Metastatic Gastrointestinal Neuroendocrine Tumors Treated with PRCRT Using 177 Lu-DOTATATE with Capecitabine as Radiosensitizer

Introduction: Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE is gaining acceptance as safe and effective therapy for inoperable neuroendocrine tumors (NET). A radiosensitizing chemotherapeutic drug -capecitabine, the prodrug of 5-Flourouracil, is included in the protocol to further enhance therapeutic efficacy.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Dureja S

Authors: Dureja S, Thakral P, Pant V, Pallavi U, Vindhya M,

Keywords: PRRT, radiosensitizer,